Healthcare and life sciences rank among the world’s most valuable sectors, spanning pharmaceutical manufacturers, medical device developers and biotech firms. These companies are ranked by equity market capitalisation – calculated as the share price at close on 30 April 2026 multiplied by the total number of ordinary shares in issue.
Our rankings below show the leading healthcare companies worldwide by market capitalisation as of 30 April 2026. Each company’s market cap is presented in US dollars (USD), together with its latest share price and primary listing country.
| Rank | Company | Market cap (USD) | Share price (USD) | Country |
|---|---|---|---|---|
| 1 | UnitedHealth | $336.7bn | $370.74 | USA |
| 2 | CVS Health | $107.5bn | $83.90 | USA |
| 3 | McKesson | $100.8bn | $822.63 | USA |
| 4 | HCA Healthcare | $96.7bn | $434.78 | USA |
| 5 | Elevance Health | $81.8bn | $376.63 | USA |
| 6 | The Cigna Group | $77.1bn | $292.32 | USA |
| 7 | Cencora | $60.6bn | $311.43 | USA |
| 8 | Cardinal Health | $47.7bn | $202.82 | USA |
| 9 | Siemens Healthineers | $44.5bn | $39.84 | Germany |
| 10 | Medline | $36.7bn | $43.40 | USA |
| 11 | Fresenius | $26.8bn | $47.55 | Germany |
| 12 | Centene | $26.7bn | $53.98 | USA |
| 13 | Dr. Sulaiman Al Habib Medical Services Group Company | $22.6bn | $64.45 | S. Arabia |
| 14 | IHH Healthcare | $20.1bn | $2.22 | Malaysia |
| 15 | JD Health | $18.6bn | $5.79 | China |
The information on this page is based on data from public company disclosures, including SEC filings and other regulatory sources such as EDGAR. It is provided for informational purposes only and does not constitute investment advice or a recommendation to trade. While considered accurate as of the stated dates, figures may change without notice.
Market capitalisation is a common way to measure a healthcare company's size and market value. It is calculated by multiplying the current share price by the total number of ordinary shares outstanding, so it moves as the share price changes. In healthcare, those moves can reflect earnings expectations, clinical trial results, drug approvals, regulation, and reimbursement policy. This means market cap can show how the market values a company at a given time, but not why that value may change next. The wider healthcare services market – covering hospitals, insurers, distributors, and device makers – was valued at $9.33 trillion in 2026, up from $8.94 trillion in 2025, with a compound annual growth rate (CAGR) of 4.4% (Research and Markets, accessed 30 April 2026). That broader backdrop helps explain why some healthcare companies command large valuations, even though company-specific events can still shift market cap sharply.
The managed care segment – including UnitedHealth, CVS Health, Elevance Health, Cigna, and Centene – is operating against a backdrop of margin pressure and regulatory change. The Centers for Medicare & Medicaid Services (CMS) approved a net average Medicare Advantage rate increase of 2.48% for 2027, representing more than $13 billion in additional payments to plans, which supported a broad rally in managed care stocks in early April 2026 (Reuters, 6 April 2026). At the same time, Medicare Advantage enrolment growth is expected to slow to 4–5% annually from 2024 to 2029, down from 8–9% between 2019 and 2024 (McKinsey, 12 January 2026). That points to a mixed picture, where higher payment rates may support revenue while slower enrolment growth and cost pressure may weigh on margins. The ACA marketplace segment also faces pressure following the expiration of enhanced premium tax credits at the end of 2025, which are no longer available to the approximately 18 million Americans who had relied on them (Avalere Health, 1 April 2025). Taken together, these shifts show how policy can influence valuations in different ways across the sector.
McKesson, Cardinal Health, and Cencora – ranked third, eighth, and seventh respectively – dominate pharmaceutical wholesale distribution in the United States and handle a significant share of the country's drug supply. Their scale has made them central to the healthcare supply chain, and recent share price performance has reflected that position. All three stocks delivered returns that outperformed the broader market heading into 2026, with Cardinal Health up 66.4%, McKesson up 39.5%, and Cencora gaining 42.2% over the same period (Yahoo Finance, 12 January 2026). Even so, scale does not remove pressure. The 'Big Three' face competitive challenges from consolidating hospital systems, direct purchasing initiatives, and continued margin scrutiny, while McKesson's third-quarter fiscal 2026 revenues rose 11% and Cardinal Health's second-quarter revenues grew 19%, reflecting ongoing specialty drug demand across the sector (Zacks, 24 March 2026). Cencora has committed to investing over $1 billion through 2030 to expand its US drug distribution network after posting an above-consensus fiscal 2026 profit forecast (Reuters, 5 November 2025). This highlights how strong market positions can support growth, while competition and pricing pressure can still affect outlook and valuation.
Healthcare investing refers to gaining exposure to companies involved in medical services, biotechnology, pharmaceuticals, medical devices, health insurance, digital health and related fields. Traders can buy shares directly or speculate on price changes through contracts for difference (CFDs). CFDs are traded on margin, with leverage amplifying both profits and losses – and do not provide dividend rights, as they don’t involve ownership of the underlying asset. Prices in the sector may move in response to drug approvals, clinical-trial outcomes, regulatory updates, patent decisions, mergers and acquisitions, earnings announcements and wider economic conditions.
To trade healthcare share CFDs, you’ll need to open and verify an account with a locally regulated CFD provider using identity and residency documents. Once the account is active, deposit funds, access the trading platform and familiarise yourself with margin requirements. It can also be useful to practise with a demo account to understand how CFD trading works before committing real funds.
Start by understanding each company’s revenue streams, product pipelines and regulatory exposure, as well as the impact of leverage and volatility. Risk management tools such as stop-loss orders, position sizing, and managing margin levels can help control your exposure and potentially limit risks. Standard stop-losses are not guaranteed. Guaranteed stop-loss orders (GSLOs) incur a fee if activated.
Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.
Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.
Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️
I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.
Love the TV integration. Makes traders life smooth and comfortable.
I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!
I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!
This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one
User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.
Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!
Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.
Why choose Capital.com? Our numbers speak for themselves
Capital.com Group
Ratings and Reviews
Ratings and Reviews